[Clinical features of acute B lymphoblastic leukemia with TAF15::ZNF384 fusion gene].

A retrospective analysis was conducted on the clinical data of acute B lymphoblastic leukemia (B-ALL) patients with TAF15::ZNF384 fusion gene positive at Hebei Yanda Ludaopei Hospital from December 2018 to February 2022. The patients were followed up until December 2024 to analyze their clinical characteristics and outcomes. A total of 6 patients were included, including 4 males and 2 females, aged 16 to 47 years. The follow-up period ranged from 10 days to 65 months. All 6 patients sought medical attention due to incomplete remission (CR) after treatment at an external hospital or short-term recurrence after CR. Five of the 6 patients presented with chromosomal abnormalities at initial diagnosis, including 4 with t(12;17) (p13;q12) chromosomal translocation. Immunophenotyping showed the B lymphatic system markers CD19, CD22, and cytoplasmic CD79a were positive in all cases, accompanied by positive myeloid markers such as CD33 or CD31. Four patients showd positive expression of the lymphoid maker CD10. Among the 6 patients, 4 patients achieved CR after receiving chimeric antigen receptor T-cell (CAR-T) therapy, and maintained CR after bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT). B-ALL patients harboring the TAF15::ZNF384 fusion gene often present with complex chromosomal abnormalities at the initial diagnosis and the immunophenotype is often characterized by B lymphatic system with positive myeloid markers. CAR-T immunotherapy followed by allo-HSCT may offer a promising approach to improving their prognosis.